PureTech Health plc (NASDAQ:PRTC – Get Rating) – Stock analysts at Jefferies Financial Group issued their FY2022 EPS estimates for shares of PureTech Health in a report issued on Thursday, October 13th. Jefferies Financial Group analyst P. Welford expects that the company will post earnings of ($4.00) per share for the year. The consensus estimate for PureTech Health's current full-year earnings is ($3.66) per share. Jefferies Financial Group also issued estimates for PureTech Health's FY2023 earnings at ($5.00) EPS, FY2024 earnings at ($5.00) EPS, FY2025 earnings at ($6.00) EPS and FY2026 earnings at ($6.00) EPS.

Separately, Piper Sandler upped their price target on shares of PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a report on Thursday, August 25th.

PureTech Health Stock Performance

Institutional Investors Weigh In On PureTech Health

An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. raised its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 at the end of the most recent reporting period. 2.32% of the stock is owned by institutional investors and hedge funds.

PureTech Health Company Profile

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

See Also

• Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
• Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
• This Mid Cap Energy Stock is a 10-Bagger...And May Not Be Done
• Should You Make a Reservation in Marriott International Stock?
• The Outperforming Software Stock No One is Talking About
• Will Goldman Sachs' Earnings & Revenue Beats Lift Sector Higher?

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.